Start Allopurinol as First-Line Urate-Lowering Therapy
You should give allopurinol, not febuxostat, as the preferred first-line urate-lowering therapy for this patient. The 2020 American College of Rheumatology guidelines strongly recommend allopurinol over all other urate-lowering agents, including febuxostat, based on its efficacy, tolerability, safety profile, and lower cost 1.
Dosing Strategy
Start with low-dose allopurinol at ≤100 mg daily (or even lower at 50 mg daily if you want to be extra cautious), then titrate upward by 100 mg increments at weekly to monthly intervals until serum urate reaches <6 mg/dL 1, 2. The maximum FDA-approved dose is 800 mg/day. This "start-low go-slow" approach significantly reduces the risk of triggering additional gout flares during initiation 1.
Critical: Continue colchicine prophylaxis for 3-6 months after starting allopurinol 1. The FDA label explicitly states that "maintenance doses of colchicine generally should be given prophylactically when allopurinol tablets are begun" 2. Recent evidence confirms this is necessary—a 2023 trial demonstrated that placebo was NOT non-inferior to colchicine, meaning patients who didn't receive colchicine prophylaxis had significantly more gout flares (0.61 vs 0.35 flares/month) 3.
Why Allopurinol Over Febuxostat?
The guidelines are unequivocal: allopurinol is the strongly recommended first-line agent with moderate certainty of evidence 1. While febuxostat can achieve lower serum urate levels at fixed doses 4, when both drugs are properly titrated to target using treat-to-target strategies, they achieve similar efficacy. A 2022 VA trial of 940 patients showed allopurinol was non-inferior to febuxostat for controlling flares, with 80% of patients in both groups reaching target urate levels 5.
More importantly, febuxostat carries potential cardiovascular safety concerns. A 2026 real-world study found febuxostat associated with modestly increased all-cause mortality (HR 1.125) compared to allopurinol in patients with preexisting cardiovascular disease 6. Given allopurinol's proven track record, lower cost, and equivalent efficacy when dosed appropriately, there's no reason to start with febuxostat.
Practical Implementation
- Week 0: Start allopurinol 100 mg daily (or 50 mg if very cautious)
- Continue colchicine 0.6 mg once or twice daily for prophylaxis 1, 7
- Weekly to monthly: Increase allopurinol by 100 mg increments
- Target: Serum urate <6 mg/dL
- Duration of prophylaxis: Minimum 3-6 months, potentially longer if flares continue 1
Common Pitfalls to Avoid
- Don't stop colchicine too early: The evidence shows stopping before 3 months leads to rebound flares 3, 8
- Don't use fixed-dose allopurinol (300 mg): Many patients need higher doses (up to 800 mg) to reach target urate 1, 5
- Don't skip the low starting dose: Starting high increases flare risk and hypersensitivity reactions 1, 2
- Don't reserve febuxostat as first-line: It should be second-line if allopurinol fails or is contraindicated 1
The 2024 study comparing treat-to-target allopurinol versus febuxostat found no difference in flare rates when both were properly titrated with optimal prophylaxis (HR 1.17, not significant) 9, confirming that proper allopurinol dosing achieves the same outcomes as febuxostat without the cost or potential cardiovascular concerns.